Simin Baygani
Overview
Explore the profile of Simin Baygani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacGregor E, Komori M, Krege J, Baygani S, Vincent M, Pavlovic J, et al.
Cephalalgia
. 2022 Aug;
42(14):1467-1475.
PMID: 35979677
Background: Perimenstrual migraine attacks in women with menstrual migraine is difficult to treat. This post-hoc analysis evaluated the efficacy of lasmiditan, a high affinity and selective 5-HT receptor agonist, for...
2.
Rabe H, Bhatt-Mehta V, Bremner S, Ahluwalia A, Mcfarlane R, Baygani S, et al.
J Perinatol
. 2021 Aug;
41(9):2317-2329.
PMID: 34365475
Objective: A comprehensive understanding of the factors contributing to perinatal blood pressure is vital to ensure optimal postnatal hemodynamic support. The objective of this study was to review existing literature...
3.
Ivy D, Bonnet D, Berger R, Meyer G, Baygani S, Li B
Pulm Circ
. 2021 Jul;
11(3):20458940211024955.
PMID: 34234945
This study evaluated the efficacy and safety of tadalafil in pediatric patients with pulmonary arterial hypertension. This phase-3, international, randomized, multicenter (24 weeks double-blind placebo-controlled period; two-year, open-labeled extension period),...
4.
Knievel K, Buchanan A, Lombard L, Baygani S, Raskin J, Krege J, et al.
Cephalalgia
. 2019 Nov;
40(1):19-27.
PMID: 31744319
Background: Lasmiditan demonstrated superiority to placebo in the acute treatment of migraine in adults with moderate/severe migraine disability in two similarly designed Phase 3 trials, SAMURAI and SPARTAN. Post-hoc integrated...
5.
Shen Loo L, Ailani J, Schim J, Baygani S, Hundemer H, Port M, et al.
J Headache Pain
. 2019 Jul;
20(1):84.
PMID: 31340760
Objective: To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications. Background: While lasmiditan has been proven to be an effective...
6.
Davis J, Baer G, Portman R, Nelson R, Storari L, Aranda J, et al.
Clin Ther
. 2017 Oct;
39(10):1959-1969.
PMID: 28987269
Because the highest rates of morbidity and mortality in neonates are seen in those born at <32 weeks' gestation, this group has the most urgent need for novel therapies to...
7.
Gamalo-Siebers M, Savic J, Basu C, Zhao X, Gopalakrishnan M, Gao A, et al.
Pharm Stat
. 2017 Apr;
16(4):232-249.
PMID: 28448684
Children represent a large underserved population of "therapeutic orphans," as an estimated 80% of children are treated off-label. However, pediatric drug development often faces substantial challenges, including economic, logistical, technical,...
8.
McVary K, Peterson A, Donatucci C, Baygani S, Henneges C, Clouth J, et al.
J Urol
. 2016 Apr;
196(3):824-30.
PMID: 27105760
Purpose: Lower urinary tract symptoms associated with benign prostatic hyperplasia typically respond well to medical therapy. While changes in total I-PSS (International Prostate Symptom Score) are generally accepted as measurement...
9.
Mulhall J, Brock G, Glina S, Baygani S, Donatucci C, Maggi M
J Sex Med
. 2016 Mar;
13(5):843-51.
PMID: 27017071
Introduction: Controversy exists as to whether erectile response to phosphodiesterase type 5 inhibitors is compromised in men with low total testosterone (TT) levels. This is amplified by reports of improved...
10.
Kim E, Seftel A, Goldfischer E, Baygani S, Burns P
Curr Med Res Opin
. 2014 Dec;
31(2):379-89.
PMID: 25455432
Objective: Phosphodiesterase type-5 inhibitors (PDE5Is) are first-line therapies for erectile dysfunction (ED). Sildenafil (SIL) and vardenafil (VAR) are approved for as-needed (PRN) dosing; tadalafil (TAD) is approved for both PRN...